In:
Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-6-17)
Abstract:
Clear cell renal cell carcinoma (ccRCC) is known for its high drug resistance. The tumor-immune crosstalk mediated by the epigenetic regulation of N6-methyladenosine (m 6 A) modification has been demonstrated in recent studies. Therefore, m 6 A modification-mediated immune cell infiltration characteristics may be helpful to guide immunotherapy for ccRCC. Methods This study comprehensively analyzed m 6 A modifications using the clinical parameters, single-cell RNA sequencing data, and bulk RNA sequencing data from the TCGA-ccRC cohort and 13 external validation cohorts. A series of bioinformatic approaches were applied to construct an m 6 A regulator prognostic risk score (MRPRS) to predict survival and immunotherapy response in ccRCC patients. Immunological characteristics, enriched pathways, and mutation were evaluated in high- and low-MRPRS groups. Results The expressional alteration landscape of m 6 A regulators was profiled in ccRCC cell clusters and tissue. The 8 regulator genes with minimal lambda were integrated to build an MRPRS, and it was positively correlated with immunotherapeutic response in extent validation cohorts. The clinicopathological features and immune infiltration characteristics could be distinguished by the high- and low-MRPRS. Moreover, the MRPRS-mediated mutation pattern has an enhanced response to immune checkpoint blockade in the ccRCC and pan-cancer cohorts. Conclusions The proposed MRPRS is a promising biomarker to predict clinical outcomes and therapeutic responses in ccRCC patients.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2022.818120
DOI:
10.3389/fimmu.2022.818120.s001
DOI:
10.3389/fimmu.2022.818120.s002
DOI:
10.3389/fimmu.2022.818120.s003
DOI:
10.3389/fimmu.2022.818120.s004
DOI:
10.3389/fimmu.2022.818120.s005
DOI:
10.3389/fimmu.2022.818120.s006
DOI:
10.3389/fimmu.2022.818120.s007
DOI:
10.3389/fimmu.2022.818120.s008
DOI:
10.3389/fimmu.2022.818120.s009
DOI:
10.3389/fimmu.2022.818120.s010
DOI:
10.3389/fimmu.2022.818120.s011
DOI:
10.3389/fimmu.2022.818120.s012
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8
Permalink